Herein, the novel combination of NO, delivered via S-Nitrosoglutathione (GSNO) (Figure 1a), and SMYD3 inhibition, with inhibitor-4 (Figure 1b), is investigated for anticancer potential against breast cancers. Here, SMYD3 is linked to breast cancer.